Home » Newsletters » BioWorld Science

BioWorld Science

Nov. 3, 2021

View Archived Issues

ADAM9 is a driver of disease severity in COVID-19 and a potential therapeutic target

LncRNA LINC00978 is a potential diagnostic marker of colorectal cancer

SAR-439883 rescues memory deficits and prevents neurodegeneration in animal models of AD

Targeting IRE1-mediated ER stress response and lipid reshuffling for reprogramming TME

PF-00835231 and its prodrug PF-07304814 show promising SARS-CoV-2 antiviral activity

Sanofi patents new YAP1/TEAD interaction inhibitors

Foghorn Therapeutics discloses new PROTACs

UCB identifies new IL-17 modulators

GB005 synthesizes BTK inhibitors

U.S. researchers patent new meayamycin derivatives

Mechanism of KRAS-G12C inhibitors unveiled: RGS3 enhances the GTPase activity of mutant and WT KRAS

KDM5B suppresses antitumor immunity by epigenetic silencing of retroelements in melanoma models

Detachable glucosylated PEG chains allow anti-PD-L1 antibody access to glioblastoma tumors

Low glycemic diets alter lipid availability and influence cancer cell metabolism to affect growth

FTD3-associated reactive astrocytes display autophagy impairments and cause neuronal toxicity

Angelman syndrome gene therapy restores dual-isoform expression of UBE3A in the developing brain

Structure-based optimization identifies potent galactokinase inhibitors

New treatment targets identified in opiate abstinence

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for June 12, 2026.
News in brief
BioWorld Asia
BioWorld Asia briefs for June 9, 2026
Pre-disease plasma signature may help redefine lung cancer risk
BioWorld
Researchers have identified a 14-protein blood signature that can predict lung cancer risk as much as five years before diagnosis, and the findings could help...
Europe’s Alzecure, Orionis in $1B+ deals with Lilly, Novartis
BioWorld
Two companies with European ties signed billion-dollar deals with large pharma firms in the last two days to discover and develop molecular glue drugs, as well as...
Ethyreal launches to treat the underlying cause of Graves’, TED
BioWorld
Ethyreal Bio Inc. has come out of stealth mode in order to disclose preclinical data for ETHY-001, its monoclonal antibody targeting thyroid stimulating hormone...